Bevantolol Hydrochloride()

Carvanol (Carvan) is a prescription drug approved and launched in Japan in June 1995. Its main therapeutic targets include β1-adrenergic receptors, α1-adrenergic receptors, and L-type voltage-gated calcium channels. It should be used strictly under medical supervision.

Targets of Action

β1-adrenergic receptors, α1-adrenergic receptors, and L-type voltage-gated calcium channels.

Dosage and Administration

Route and frequency of administration for Bevantolol Hydrochloride: Oral administration.

The dosage of bevantolol should be adjusted according to the patient’s actual condition. For specific guidance, consult a physician and use strictly as directed.

Recommended reading: Dosage and Administration of Bevantolol Hydrochloride

Adverse Reactions

Common side effects: Bradycardia, dizziness, headache.

Serious side effects: Cardiac conduction and function suppression, bronchospasm.

Reference article: Adverse Reactions of Bevantolol Hydrochloride

Use in Special Populations

Pregnancy: Contraindicated.

Lactation: A careful assessment should be made between the therapeutic need and the benefits of breastfeeding before deciding whether to continue breastfeeding or discontinue the drug.

Precautions for Daily Use

1. For long-term administration, regular cardiac function tests (pulse, blood pressure, ECG, X-ray, etc.) are required. If bradycardia or hypotension occurs, the dosage should be reduced or administration discontinued. Atropine sulfate hydrate may be used if necessary. Monitoring of liver function, renal function, blood parameters, and other indicators is also advised.

2. Avoid administration within 48 hours prior to surgery.

3. This drug may cause dizziness, unsteady standing, etc. Patients receiving this drug (especially at the initial stage of treatment) should be cautioned to avoid hazardous mechanical operations such as driving a motor vehicle.